A Phase 2 interventional study of GDC-0853 and Adalimumab in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed at 150 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-12.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 19th largest by enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2016, is one of 20 in phase 2, and was the 212th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Brazil, Poland
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Belgium and 9 more countries
Ages 18+
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
219 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 22 · Phase 3 85 · Phase 4 28
First in 2001; this study’s year is marked. 8 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 578 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 132 across the 141 interventional studies, 182 across the 78 observational. Of the 214 that completed or were terminated, 139 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
1 of the studies in Arthritis, Rheumatoid by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
Add it to your calendar (.ics) → With an account.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to severe active RA and an inadequate response to previous methotrexate (MTX) therapy (Cohort 1) or MTX and tumor necrosis factor (TNF) therapy who may have also had exposure to no more than one non-TNF inhibitor biologic (Cohort 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants of Cohort 1 will receive GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Drug: GDC-0853 · Drug: Folic Acid · Drug: MTX · Drug: Placebo
Participants of Cohort 1 will receive GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Drug: GDC-0853 · Drug: Folic Acid · Drug: MTX · Drug: Placebo
Participants of Cohort 1 will receive GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Drug: GDC-0853 · Drug: Folic Acid · Drug: MTX · Drug: Placebo
Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Drug: Adalimumab · Drug: Folic Acid · Drug: MTX · Drug: Placebo
Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Drug: Folic Acid · Drug: MTX · Drug: Placebo
Participants of Cohort 2 will receive GDC-0853 high dose, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Drug: GDC-0853 · Drug: Folic Acid · Drug: MTX
Participants of Cohort 2 will receive placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Drug: Folic Acid · Drug: MTX · Drug: Placebo
Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Also known as: RO7010939
Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1)
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Day 84
Percentage of Participants With Adverse Events
An Adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE was any experience that suggested a significant hazard, contraindication, side effect or precaution that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.
Time frame: Day 1 up to 8 weeks after last dose (up to Week 20)
Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Adalimumab (Cohort 1)
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Day 84
Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 2)
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Day 84
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]
Time frame: Days 7, 14, 28, 56, and 84
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Days 7, 14, 28, 56, and 84
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Days 7, 14, 28, 56, and 84
Change in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
Time frame: Days 7, 14, 28, 56, and 84
Change in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
Time frame: Days 7, 14, 28, 56, and 84
Change in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
Time frame: Days 7, 14, 28, 56, and 84
Change in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
Time frame: Days 7, 14, 28, 56, and 84
Percentage of Participants With DAS Low Disease Activity
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2
Time frame: Days 7, 14, 28, 56, and 84
Percentage of Participants With DAS Remission
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6
Time frame: Days 7, 14, 28, 56, and 84
Percentage of Participants Meeting the Boolean-based Remission Criteria
Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale).
Time frame: Days 7, 14, 28, 56, and 84
Change From Baseline in Clinical Disease Activity Index (CDAI)
CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.
Time frame: Baseline, Days 7, 14, 28, 56 and 84
Percentage of Participants Meeting the CDAI-based Remission Criteria
Clinical Disease Activity Index is defined as CDAI= : SJC(28) + TJC(28) + PGA + MDG where TJC and SJC are the tender and swollen joint counts from 28 joints, PGA is the patient's global assessment of disease activity (on a 0-10 scale) and MDG is physician global assessment of disease activity (on a 0-10 scale). The cutoff value for CDAI remission is \<=2.8.
Time frame: Days 7, 14, 28, 56, and 84
Change From Baseline in Simplified Disease Activity Index (SDAI)
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity
Time frame: Baseline, Days 7, 14, 28, 56 and 84
Percentage of Participants Meeting the SDAI-based Remission Criteria
The SDAI was the numerical sum of five outcome parameter: SJC and TJC (based on a 28-joint assessment), PGA and MDG (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. The SDAI =\< 3.3 indicates disease remission
Time frame: Days 7, 14, 28, 56, and 84
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components
The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. The SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.
Time frame: Day 84
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). A total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue).
Time frame: Day 84
Change From Baseline in Tender/Painful Joint Count (68 Joint Count)
Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.
Time frame: Days 7, 14, 28, 56, and 84
Change From Baseline in Swollen Joint Count (66 Joint Count)
Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.
Time frame: Days 7, 14, 28, 56, and 84
Change From Baseline in Patient Assessment Score of Arthritis Pain
Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain
Time frame: Days 7, 14, 28, 56, and 84
Change From Baseline in Patient Global Assessment Score of Arthritis Pain
Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain.
Time frame: Days 7, 14, 28, 56, and 84
Change From Baseline in Physician's Global Assessment Score of Arthritis
Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity.
Time frame: Days 7, 14, 28, 56, and 84
Change From Baseline in C-Reactive Protein (CRP) Levels
C-reactive protein is a biological marker of inflammation and is measured in nanograms per milliliter (ng/mL)
Time frame: Days 7, 14, 28, 56, and 84
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. To respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement.
Time frame: Days 7, 14, 28, 56, and 84
Area Under the Concentration Time Curve From Time 0 to Time 24 of GDC-0853 at Steady State (AUC0-24,ss)
The Pharmacokinetics (PK) evaluation may include, but will not be limited to, plasma GDC-0853 concentrations and population PK model estimated PK exposures (area under the plasma concentration-time curve \[AUC\]. AUC was measured in Nanograms(ng) per millilitre(mL)\*hour (hr)
Time frame: Pre-dose (0 hours) up to 10 hours post-dose on Day 28
Maximum Observed Plasma Concentration of GDC-0853 at Steady State (Cmax,ss)
Cmax is the maximum (peak) plasma concentration over the dosing interval at steady state (ss)
Time frame: Pre-dose (0 hours) up to 10 hours post-dose on Day 28
Minimum Observed Plasma Concentration of GDC-0853 at Steady State (Cmin,ss)
Cmin is the minimum concentration over the dosing interval at steady state (ss)
Time frame: Pre-dose (0 hours) up to 10 hours post-dose on Day 28
578 participants were enrolled in the study and 578 were dosed. One (1) subject in Cohort 2 in the Placebo arm was incorrectly dosed with the High Dose. The ITT data set included participants according to their randomization while SAF data set included participants according to the treatment administered.
| Milestone | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Started | 40 | 109 | 110 | 110 | 111 | 49 | 49 |
| Randomized | 40 | 109 | 110 | 110 | 111 | 48 | 50 |
| Completed | 37 | 100 | 102 | 102 | 108 | 48 | 44 |
| Not completed | 3 | 9 | 8 | 8 | 3 | 1 | 5 |
| Withdrew: Adverse event | 0 | 3 | 4 | 4 | 1 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 1 | 4 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 3 | 2 | 0 | 2 | 0 | 2 |
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab |
|---|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1) | 17.5 (5.72 to 29.28) | 27.5 (19.14 to 35.91) | 34.5 (25.66 to 43.43) | 14.5 (7.96 to 21.13) | 36.0 (27.10 to 44.97) |
An Adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE was any experience that suggested a significant hazard, contraindication, side effect or precaution that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.
| Percentage | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events | 37.5 | 42.2 | 50.9 | 45.5 | 45.0 | 22.4 | 44.9 |
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab |
|---|---|---|---|---|---|
| Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Adalimumab (Cohort 1) | 17.5 (5.72 to 29.28) | 27.5 (19.14 to 35.91) | 34.5 (25.66 to 43.43) | 14.5 (7.96 to 21.13) | 36.0 (27.10 to 44.97) |
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|
| Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 2) | 25.0 (12.75 to 37.25) | 12.0 (2.99 to 21.01) |
ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]
| Percentage | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | 10.0 (.70 to 19.3) | 14.7 (8.04 to 21.32) | 13.6 (7.22 to 20.05) | 10.0 (4.39 to 15.61) | 25.2 (17.15 to 33.30) | 22.9 (11.03 to 34.81) | 2.0 (0.00 to 5.88) |
| Week 2 Day 14 | 12.5 (2.25 to 22.75) | 19.3 (11.86 to 26.67) | 27.3 (18.95 to 35.60) | 16.4 (9.45 to 23.28) | 48.6 (39.35 to 57.95) | 25.0 (12.75 to 37.25) | 10.0 (1.68 to 18.32) |
| Week 4 Day 28 | 30.0 (15.80 to 44.20) | 34.9 (25.92 to 43.81) | 41.8 (32.60 to 51.04) | 25.5 (17.31 to 33.59) | 59.5 (50.33 to 68.59) | 35.4 (21.89 to 48.95) | 24.0 (12.16 to 35.84) |
| Week 8 Day 56 | 50.0 (34.51 to 65.49) | 52.3 (42.92 to 61.67) | 58.2 (48.96 to 67.40) | 37.3 (28.24 to 46.31) | 71.2 (62.74 to 79.60) | 47.9 (33.78 to 62.05) | 18.0 (7.35 to 28.65) |
| Week 12 Day 84 | 60.0 (44.82 to 75.18) | 56.0 (46.64 to 65.28) | 59.1 (49.90 to 68.28) | 36.4 (27.37 to 45.35) | 72.1 (63.73 to 80.42) | 58.3 (44.39 to 72.28) | 24.0 (12.16 to 35.84) |
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | 2.5 (0.00 to 7.34) | 2.8 (0.00 to 5.82) | 3.6 (0.14 to 7.13) | 2.7 (0.00 to 5.77) | 4.5 (0.65 to 8.36) | 6.3 (0.00 to 13.10) | 2.0 (0.00 to 5.88) |
| Week 2 Day 14 | 0.0 (0.00 to 0.00) | 1.8 (0.00 to 4.35) | 7.3 (2.42 to 12.13) | 2.7 (0.00 to 5.77) | 9.0 (3.68 to 14.34) | 10.4 (1.77 to 19.06) | 0.00 (0.00 to 0.00) |
| Week 4 day 28 | 5.0 (0.00 to 11.75) | 9.2 (3.76 to 14.59) | 10.0 (4.39 to 15.61) | 6.4 (1.80 to 10.93) | 25.2 (17.15 to 33.30) | 10.4 (1.77 to 19.06) | 6.0 (0.00 to 12.58) |
| Week 8 Day 56 | 15.0 (3.93 to 26.07) | 18.3 (11.08 to 25.62) | 22.7 (14.9 to 30.56) | 17.3 (10.21 to 24.34) | 32.4 (23.72 to 41.14) | 22.9 (11.03 to 34.81) | 10.0 (1.68 to 18.32) |
| Week 12 Day 84 | 17.5 (5.72 to 29.28) | 27.5 (19.14 to 35.91) | 34.5 (25.66 to 43.43) | 14.5 (7.96 to 21.13) | 36.0 (27.10 to 44.97) | 25.0 (12.75 to 37.25) | 12.0 (2.99 to 21.01) |
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | 0.0 (0.00 to 0.00) | 0.9 (0.00 to 2.71) | 0.9 (0.00 to 2.68) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
| Week 2 Day 14 | 0.0 (0.00 to 0.00) | 0.9 (0.00 to 2.71) | 0.0 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 3.6 (0.14 to 7.07) | 4.2 (0.00 to 9.82) | 0.0 (0.00 to 0.00) |
| Week 4 Day 28 | 0 (0.00 to 0.00) | 2.8 (0.00 to 5.82) | 4.5 (0.65 to 8.44) | 0.9 (0.00 to 2.68) | 6.3 (1.78 to 10.83) | 2.1 (0.00 to 6.12) | 2.0 (0.00 to 5.88) |
| Week 8 Day 56 | 0.0 (0.00 to 0.00) | 7.3 (2.44 to 12.24) | 9.1 (3.72 to 14.46) | 3.6 (0.14 to 7.13) | 14.4 (7.88 to 20.95) | 6.3 (0.00 to 13.10) | 4.0 (0.00 to 9.43) |
| Week 12 Day 84 | 5.0 (0.00 to 11.75) | 9.2 (3.76 to 14.59) | 12.7 (6.50 to 18.96) | 7.3 (2.42 to 12.13) | 18.0 (10.87 to 25.17) | 14.6 (4.60 to 24.57) | 4.0 (0.00 to 9.43) |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -0.34 ± 0.60 | -0.35 ± 0.66 | -0.37 ± 0.80 | -0.33 ± 0.84 | -0.92 ± 0.71 | -0.49 ± 0.84 | -0.36 ± 0.63 |
| Week 2 Day 14 | -0.47 ± 0.72 | -0.63 ± 0.84 | -0.70 ± 0.80 | -.54 ± 0.90 | -1.09 ± 0.81 | -0.65 ± 0.87 | -0.45 ± 0.69 |
| Week 4 Day 28 | -0.75 ± 0.86 | -0.90 ± 0.96 | -0.91 ± 0.97 | -0.62 ± 1.04 | -1.45 ± 0.87 | -0.77 ± 0.90 | -0.44 ± 0.84 |
| Week 8 Day 56 | -1.14 ± 0.90 | -1.35 ± 1.12 | -1.37 ± 1.11 | -1.08 ± 1.19 | -1.75 ± 0.98 | -1.33 ± 0.98 | -0.56 ± 0.87 |
| Week 12 Day 84 | -1.30 ± 0.95 | -1.72 ± 1.11 | -1.70 ± 1.02 | -1.17 ± 1.24 | -1.87 ± 1.02 | -1.62 ± 1.15 | -0.86 ± 1.03 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -0.43 ± 0.67 | -0.48 ± 0.73 | -0.49 ± 0.86 | -0.37 ± 0.91 | -1.10 ± 0.75 | -0.63 ± 0.91 | -.40 ± 0.69 |
| Week 2 Day 14 | -0.51 ± 0.85 | -0.77 ± 0.86 | -0.84 ± 0.86 | -0.57 ± 1.00 | -1.26 ± 0.89 | -0.81 ± 0.98 | -0.54 ± 0.80 |
| Week 4 Day 28 | -0.88 ± 0.90 | -1.06 ± 1.02 | -1.08 ± 1.03 | -0.65 ± 1.16 | -1.61 ± 0.94 | -0.95 ± 1.04 | -0.55 ± 0.94 |
| Week 8 Day 56 | -1.31 ± 0.91 | -1.56 ± 1.21 | -1.57 ± 1.16 | 1.20 ± 1.30 | -1.97 ± 1.03 | -1.51 ± 1.05 | -0.67 ± 1.01 |
| Week 12 Day 84 | -1.53 ± 0.95 | -1.97 ± 1.20 | -1.93 ± 1.11 | -1.33 ± 1.33 | -2.06 ± 1.08 | -1.83 ± 1.22 | -1.00 ± 1.11 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -0.35 ± 0.57 | -0.42 ± 0.65 | -0.39 ± 0.68 | -0.34 ± 0.86 | -0.72 ± 0.72 | -0.50 ± 0.73 | -0.31 ± 0.60 |
| Week 2 Day 14 | -0.60 ± 0.89 | -0.69 ± 0.84 | -0.68 ± 0.74 | -0.55 ± 0.92 | -1.02 ± 0.84 | -0.64 ± 0.81 | -0.51 ± 0.73 |
| Week 4 Day 28 | -0.88 ± 0.89 | -0.99 ± 0.98 | -0.97 ± 0.90 | -0.75 ± 1.02 | -1.47 ± 1.02 | -0.85 ± 0.81 | -0.50 ± 0.83 |
| Week 8 Day 56 | -1.25 ± 0.85 | -1.44 ± 1.14 | -1.40 ± 1.06 | -1.15 ± 1.19 | -1.74 ± 0.98 | -1.35 ± 0.96 | -0.70 ± 0.98 |
| Week 12 Day 84 | -1.51 ± 1.01 | -1.80 ± 1.25 | -1.80 ± 0.99 | -1.30 ± 1.22 | -1.85 ± 1.06 | -1.65 ± 1.06 | -0.94 ± 10.6 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -0.45 ± 0.63 | -0.54 ± 0.72 | -0.52 ± 0.77 | -0.37 ± 0.95 | -0.93 ± 0.76 | -0.65 ± 0.80 | -0.36 ± 0.66 |
| Week 2 Day 14 | -0.63 ± 0.98 | -0.85 ± 0.85 | -0.84 ± 0.82 | -0.58 ± 1.03 | -1.22 ± 0.94 | -0.81 ± 0.92 | -0.60 ± 0.84 |
| Week 4 Day 28 | -1.00 ± 0.95 | -1.16 ± 1.06 | -1.15 ± 0.98 | -0.79 ± 1.16 | -1.65 ± 1.11 | -1.04 ± 0.95 | -0.61 ± 0.96 |
| Week 8 Day 56 | -1.43 ± 0.88 | -1.67 ± 1.25 | -1.63 ± 1.14 | -1.29 ± 1.31 | -2.00 ± 1.06 | -1.54 ± 1.04 | -0.81 ± 1.12 |
| Week 12 Day 84 | -1.76 ± 1.04 | -2.06 ± 1.36 | -2.05 ± 1.08 | -1.46 ± 1.32 | -2.08 ± 1.14 | -1.89 ± 1.15 | -1.08 ± 1.17 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2
| Percentage of participants | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | 0.0 (0.00 to 0.00) | 0.9 (0.00 to 2.71) | 1.8 (0.00 to 4.31) | 0.0 (0.00 to 0.00) | 1.8 (0.00 to 4.28) | 2.1 (0.00 to 6.12) | 0.0 (0.00 to 0.00) |
| Week 2 day 14 | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 1.8 (0.00 to 4.31) | 0.9 (0.00 to 2.68) | 4.5 (0.65 to 8.36) | 2.1 (0.00 to 6.12) | 2.0 (0.00 to 5.88) |
| Week 4 Day 28 | 0.0 (0.00 to 0.00) | 1.8 (0.00 to 4.35) | 6.4 (1.80 to 10.93) | 1.8 (0.00 to 4.31) | 11.7 (5.73 to 17.69) | 2.1 (0.00 to 6.12) | 0.0 (0.00 to 0.00) |
| Week 8 Day 56 | 0.0 (0.00 to 0.00) | 8.3 (3.09 to 13.42) | 11.8 (5.79 to 17.85) | 3.6 (0.14 to 7.13) | 18.0 (10.87 to 25.17) | 2.1 (0.00 to 6.12) | 2.0 (0.00 to 5.88) |
| Week 12 Day 84 | 7.5 (0.00 to 15.66) | 19.3 (11.86 to 26.67) | 14.5 (7.96 to 21.13) | 3.6 (0.14 to 7.13) | 17.1 (10.11 to 24.12) | 14.6 (4.60 to 24.57) | 4.0 (0.00 to 9.43) |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6
| Percentage of participants | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 2.1 (0.00 to 6.12) | 0.0 (0.00 to 0.00) |
| Week 2 Day 14 | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.9 (0.00 to 2.68) | 0.0 (0.00 to 0.00) | 0.9 (0.00 to 2.66) | 0.00 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
| Week 4 Day 28 | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 1.8 (0.00 to 4.31) | 0.9 (0.00 to 2.68) | 4.5 (0.65 to 8.36) | 0.00 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
| Week 8 Day 56 | 0.0 (0.00 to 0.00) | 3.7 (0.14 to 7.20) | 4.5 (0.65 to 8.44) | 1.8 (0.00 to 4.31) | 9.0 (3.68 to 14.34) | 0.00 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
| Week 12 Day 84 | 2.5 (0.00 to 7.34) | 7.3 (2.44 to 12.24) | 8.2 (3.06 to 13.30) | 3.6 (0.14 to 7.13) | 9.0 (3.68 to 14.34) | 4.2 (0.00 to 9.82) | 4.0 (0.00 to 9.43) |
Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale).
| Percentage of participants | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | 0.0 (0.00 to 0.00) | 0.9 (0.00 to 2.76) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
| Week 2 Day 14 | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
| Week 4 Day 28 | 0.0 (0.00 to 0.00) | 1.0 (0.00 to 2.81) | 0.0 (0.00 to 0.00) | 0.9 (0.00 to 2.73) | 2.8 (0.00 to 5.82) | 2.1 (0.00 to 6.25) | 0.0 (0.00 to 0.00) |
| Week 8 Day 56 | 0.0 (0.00 to 0.00) | 2.0 (0.00 to 4.70) | 1.90 (0.00 to 4.56) | 1.0 (0.00 to 2.86) | 3.7 (0.14 to 7.20) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
| Week 12 Day 84 | 0.0 (0.00 to 0.00) | 2.0 (0.00 to 4.84) | 4.1 (0.17 to 8.08) | 1.0 (0.00 to 2.89) | 6.5 (1.84 to 11.12) | 8.5 (0.53 to 16.49) | 0.0 (0.00 to 6.53) |
CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -5.45 ± 7.69 | -6.70 ± 8.26 | -7.40 ± 9.97 | -4.71 ± 12.91 | -9.64 ± 8.93 | -8.61 ± 10.67 | -5.26 ± 9.79 |
| Week 2 Day 14 | -6.85 ± 11.10 | -10.33 ± 10.45 | -11.33 ± 10.47 | -7.44 ± 13.39 | -13.44 ± 10.52 | -9.64 ± 12.17 | -7.70 ± 10.64 |
| Week 4 Day 28 | -10.36 ± 10.88 | -13.84 ± 12.11 | -13.78 ± 11.46 | -9.43 ± 14.77 | -17.74 ± 10.84 | -11.83 ± 11.08 | -7.49 ± 11.46 |
| Week 8 Day 56 | -14.76 ± 10.04 | -18.61 ± 13.48 | -18.10 ± 12.99 | -15.49 ± 15.74 | -21.36 ± 11.69 | -17.38 ± 12.39 | -7.57 ± 10.51 |
| Week 12 Day 84 | -16.99 ± 11.21 | -22.05 ± 12.19 | -22.10 ± 11.83 | -17.02 ± 16.24 | -22.22 ± 11.76 | -20.42 ± 13.20 | -12.23 ± 12.06 |
Clinical Disease Activity Index is defined as CDAI= : SJC(28) + TJC(28) + PGA + MDG where TJC and SJC are the tender and swollen joint counts from 28 joints, PGA is the patient's global assessment of disease activity (on a 0-10 scale) and MDG is physician global assessment of disease activity (on a 0-10 scale). The cutoff value for CDAI remission is \<=2.8.
| Percentage of participants | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | 0.0 (0.00 to 0.00) | 0.9 (0.00 to 2.71) | 0.9 (0.00 to 2.68) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
| Week 2 Day 14 | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 1.8 (0.00 to 4.28) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
| Week 4 Day 28 | 0.0 (0.00 to 0.00) | 0.9 (0.00 to 2.71) | 0.9 (0.00 to 2.68) | 0.0 (0.00 to 0.00) | 4.5 (0.65 to 8.36) | 2.1 (0.00 to 6.12) | 0.0 (0.00 to 0.00) |
| Week 8 Day 56 | 0.0 (0.00 to 0.00) | 2.8 (0.00 to 5.82) | 5.5 (1.21 to 9.70) | 0.00 (0.00 to 0.00) | 7.2 (2.40 to 12.02) | 4.2 (0.00 to 9.82) | 0.0 (0.00 to 0.00) |
| Week 12 Day 84 | 0.0 (0.00 to 0.00) | 5.5 (1.22 to 9.79) | 6.4 (1.80 to 10.93) | 0.9 (0.00 to 2.68) | 9.9 (4.35 to 15.47) | 6.3 (0.00 to 13.10) | 6.0 (0.00 to 12.58) |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -5.36 ± 7.86 | -6.48 ± 8.87 | -6.99 ± 10.49 | -4.75 ± 13.25 | -10.86 ± 9.33 | -8.73 ± 11.21 | -5.37 ± 9.49 |
| Week 2 Day 14 | -6.50 ± 10.54 | -10.46 ± 10.97 | -11.44 ± 10.85 | -7.54 ± 13.74 | -14.39 ± 10.99 | -9.84 ± 12.29 | -8.13 ± 11.01 |
| Week 4 Day 28 | -10.53 ± 11.03 | -14.47 ± 12.41 | -14.21 ± 12.20 | -8.92 ± 15.17 | -18.87 ± 11.20 | -12.13 ± 11.13 | -7.74 ± 12.02 |
| Week 8 Day 56 | -15.25 ± 10.41 | -18.95 ± 13.80 | -18.97 ± 13.91 | -15.74 ± 16.18 | -22.62 ± 11.97 | -18.57 ± 12.80 | -7.82 ± 11.20 |
| Week 12 Day 84 | -17.54 ± 11.36 | -22.89 ± 12.52 | -23.24 ± 12.50 | -17.47 ± 16.70 | -23.33 ± 11.97 | -21.97 ± 13.78 | -12.92 ± 12.61 |
The SDAI was the numerical sum of five outcome parameter: SJC and TJC (based on a 28-joint assessment), PGA and MDG (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. The SDAI =\< 3.3 indicates disease remission
| Percentage of participants | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | 0.00 (0.00 to 0.00) | 0.9 (0.00 to 2.71) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 2 Day 14 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 1.8 (0.00 to 4.28) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 4 Day 28 | 0.00 (0.00 to 0.00) | 0.9 (0.00 to 2.71) | 0.9 (0.00 to 2.68) | 0.00 (0.00 to 0.00) | 4.5 (0.65 to 8.36) | 2.1 (0.00 to 6.12) | 0.00 (0.00 to 0.00) |
| Week 8 Day 56 | 0.00 (0.00 to 0.00) | 2.8 (0.00 to 5.82) | 3.6 (0.14 to 7.13) | 0.00 (0.00 to 0.00) | 6.3 (1.78 to 10.83) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 12 Day 84 | 0.00 (0.00 to 0.00) | 4.6 (0.66 to 8.51) | 6.4 (1.80 to 10.93) | 0.9 (0.00 to 2.68) | 9.0 (3.68 to 14.34) | 6.3 (0.00 to 13.10) | 6.0 (0.00 to 12.58) |
The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. The SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.
| Number on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Physical component score change: baseline-week 12 | 5.57 ± 5.98 | 5.71 ± 6.85 | 6.59 ± 7.54 | 3.54 ± 6.81 | 6.41 ± 6.43 | 5.35 ± 7.48 | 1.75 ± 6.39 |
| Mental component score change: baseline-week 12 | 7.04 ± 9.32 | 4.89 ± 10.57 | 6.92 ± 12.06 | 4.29 ± 10.51 | 6.50 ± 10.79 | 5.76 ± 10.22 | 5.11 ± 10.10 |
The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). A total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue).
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score | 9.00 ± 10.57 | 8.21 ± 10.22 | 8.95 ± 10.04 | 7.08 ± 10.88 | 9.59 ± 9.02 | 8.85 ± 9.57 | 5.71 ± 9.24 |
Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -2.79 ± 7.25 | -4.12 ± 8.14 | -3.33 ± 9.27 | -3.81 ± 10.85 | -5.58 ± 9.41 | -6.57 ± 8.66 | -3.06 ± 11.01 |
| Week 2 Day 19 | -4.33 ± 12.31 | -6.36 ± 10.88 | -5.91 ± 9.38 | -5.78 ± 11.50 | -8.62 ± 10.46 | -6.08 ± 8.53 | -3.92 ± 10.77 |
| Week 4 Day 28 | -6.00 ± 8.89 | -7.90 ± 11.28 | -6.84 ± 9.53 | -7.55 ± 12.97 | -11.61 ± 11.43 | -7.79 ± 7.93 | -4.40 ± 12.37 |
| Week 8 Day 56 | -9.72 ± 8.20 | -11.57 ± 12.18 | -9.75 ± 10.93 | -10.75 ± 14.37 | -14.12 ± 11.33 | -11.65 ± 10.34 | -4.60 ± 12.41 |
| Week 12 Day 84 | -10.33 ± 9.40 | -12.72 ± 12.05 | -11.49 ± 11.15 | -10.55 ± 14.37 | -15.49 ± 12.31 | -13.73 ± 12.81 | -7.14 ± 13.32 |
Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -1.84 ± 5.19 | -2.89 ± 5.01 | -3.45 ± 6.02 | -3.35 ± 9.38 | -3.94 ± 5.33 | -3.45 ± 4.90 | -1.49 ± 4.49 |
| Week 2 Day 14 | -3.95 ± 6.44 | -4.78 ± 5.99 | -5.06 ± 5.14 | -4.23 ± 9.88 | -6.26 ± 5.98 | -3.29 ± 5.69 | -2.96 ± 6.27 |
| Week 4 Day 28 | -4.38 ± 4.55 | -6.33 ± 7.98 | -5.95 ± 6.09 | -5.47 ± 9.26 | -8.50 ± 6.39 | -4.21 ± 6.39 | -3.46 ± 5.62 |
| Week 8 Day 56 | -6.54 ± 5.78 | -8.06 ± 8.13 | -7.72 ± 7.44 | -7.41 ± 10.82 | -9.60 ± 6.94 | -6.81 ± 6.16 | -3.02 ± 7.76 |
| Week 12 Day 84 | -7.36 ± 5.88 | -8.89 ± 8.23 | -8.48 ± 7.01 | -8.26 ± 11.48 | -9.94 ± 6.91 | -7.65 ± 6.75 | -4.86 ± 5.84 |
Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -9.00 ± 18.66 | -9.20 ± 20.56 | -11.18 ± 21.64 | -4.12 ± 22.43 | -15.75 ± 18.71 | -11.94 ± 21.25 | -2.76 ± 18.24 |
| Week 2 Day 14 | -6.08 ± 21.64 | -12.16 ± 20.09 | -17.08 ± 23.46 | -8.22 ± 25.72 | -18.13 ± 17.71 | -15.08 ± 21.87 | -4.72 ± 17.64 |
| Week 4 Day 28 | -13.41 ± 16.79 | -15.75 ± 21.97 | -18.63 ± 24.87 | -10.08 ± 27.16 | -20.21 ± 21.97 | -16.64 ± 27.86 | -7.54 ± 23.80 |
| Week 8 Day 56 | -18.38 ± 19.35 | -23.21 ± 22.10 | -25.95 ± 27.50 | -16.37 ± 27.65 | -24.70 ± 22.23 | -21.21 ± 27.13 | -7.13 ± 25.73 |
| Week 12 Day 84 | -23.14 ± 21.14 | -26.48 ± 23.30 | -30.63 ± 28.49 | -17.88 ± 29.42 | -26.30 ± 23.87 | -26.49 ± 27.65 | -13.98 ± 25.32 |
Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain.
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -9.00 ± 15.88 | -10.30 ± 20.82 | -11.82 ± 22.52 | -3.07 ± 20.83 | -18.33 ± 20.81 | -13.15 ± 22.17 | -4.96 ± 19.18 |
| Week 2 Day 14 | -5.50 ± 20.98 | -13.70 ± 19.63 | -14.84 ± 24.08 | -5.39 ± 26.13 | -18.94 ± 22.33 | -15.46 ± 21.67 | -8.64 ± 19.43 |
| Week 4 Day 28 | -12.11 ± 16.68 | 16.10 ± 23.48 | -17.75 ± 22.73 | -6.36 ± 25.99 | -21.78 ± 25.53 | -18.26 ± 27.53 | -10.96 ± 21.54 |
| Week 8 Day 56 | -19.19 ± 16.88 | -24.06 ± 24.99 | -22.59 ± 26.81 | -14.19 ± 29.80 | -26.77 ± 25.69 | -21.17 ± 25.98 | -11.82 ± 21.66 |
| Week 12 Day 84 | -23.33 ± 22.03 | -26.67 ± 26.89 | -27.33 ± 27.33 | -16.87 ± 28.68 | -26.24 ± 27.02 | -25.55 ± 27.52 | -13.80 ± 22.17 |
Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity.
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -7.89 ± 13.16 | -10.68 ± 15.41 | -12.82 ± 17.03 | -5.85 ± 15.44 | -14.23 ± 16.13 | -9.57 ± 17.10 | -7.66 ± 18.33 |
| Week 2 Day 14 | -11.10 ± 15.65 | -15.86 ± 16.77 | -18.30 ± 19.04 | -9.01 ± 18.07 | -21.33 ± 19.61 | -14.23 ± 18.50 | -9.85 ± 17.55 |
| Week 4 Day 28 | -16.89 ± 19.06 | -22.02 ± 18.61 | -20.92 ± 17.71 | -14.01 ± 21.03 | -28.81 ± 19.34 | -17.70 ± 20.49 | -12.73 ± 20.42 |
| Week 8 Day 56 | -24.59 ± 15.06 | -28.52 ± 21.11 | -29.67 ± 20.01 | -20.87 ± 23.85 | -36.16 ± 21.82 | -22.40 ± 20.43 | -9.91 ± 19.67 |
| Week 12 Day 84 | -26.81 ± 16.20 | -32.43 ± 19.24 | -34.48 ± 19.49 | -23.19 ± 23.39 | -37.18 ± 21.02 | -30.82 ± 21.95 | -18.44 ± 21.86 |
C-reactive protein is a biological marker of inflammation and is measured in nanograms per milliliter (ng/mL)
| (ng/mL) nanograms per milliliter | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | 0.14 ± 2.09 | 0.30 ± 2.58 | 0.22 ± 2.49 | 0.01 ± 1.29 | -1.21 ± 2.37 | -0.12 ± 2.60 | -0.10 ± 1.76 |
| Week 2 Day 14 | 0.27 ± 1.78 | -0.10 ± 1.92 | -0.21 ± 2.29 | -0.12 ± 1.53 | -0.93 ± 2.70 | -0.20 ± 2.38 | -0.25 ± 2.60 |
| Week 4 Day 28 | 0.15 ± 2.45 | -0.25 ± 2.55 | -0.44 ± 2.30 | 0.14 ± 2.00 | -1.11 ± 2.17 | -0.30 ± 2.58 | -0.24 ± 2.80 |
| Week 8 Day 56 | -0.49 ± 1.66 | -0.52 ± 1.83 | -0.89 ± 3.16 | -0.39 ± 1.64 | -1.14 ± 2.39 | -1.19 ± 2.18 | -0.26 ± 2.55 |
| Week 12 Day 84 | -0.59 ± 1.43 | -0.77 ± 1.89 | -1.30 ± 2.88 | -0.45 ± 1.71 | -1.03 ± 2.01 | -1.55 ± 2.35 | -0.56 ± 2.75 |
The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. To respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement.
| Score on a scale | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| Week 1 Day 7 | -0.20 ± 0.37 | -0.15 ± 0.35 | -0.22 ± 0.48 | -0.10 ± 0.38 | -0.26 ± 0.42 | -0.19 ± 0.36 | -0.14 ± 0.46 |
| Week 2 Day 14 | -0.24 ± 0.39 | -0.23 ± 0.46 | -0.28 ± 0.50 | -0.17 ± 0.45 | -0.35 ± 0.47 | -0.23 ± 0.45 | -0.13 ± 0.49 |
| Week 4 Day 28 | -0.34 ± 0.47 | -0.32 ± 0.48 | -0.40 ± 0.50 | -0.19 ± 0.56 | -0.50 ± 0.50 | -0.23 ± 0.42 | -0.17 ± 0.44 |
| Week 8 Day 56 | -0.49 ± 0.47 | -0.44 ± 0.56 | -0.56 ± 0.55 | -0.40 ± 0.64 | -0.60 ± 0.55 | -0.45 ± 0.50 | -0.23 ± 0.55 |
| Week 12 Day 84 | -0.51 ± 0.57 | -0.57 ± 0.57 | -0.65 ± 0.60 | -0.35 ± 0.68 | -0.65 ± 0.61 | -0.53 ± 0.61 | -0.30 ± 0.62 |
The Pharmacokinetics (PK) evaluation may include, but will not be limited to, plasma GDC-0853 concentrations and population PK model estimated PK exposures (area under the plasma concentration-time curve \[AUC\]. AUC was measured in Nanograms(ng) per millilitre(mL)\*hour (hr)
| Ng/mL*(hr) | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 2: GDC-0853 High Dose |
|---|---|---|---|---|
| Area Under the Concentration Time Curve From Time 0 to Time 24 of GDC-0853 at Steady State (AUC0-24,ss) | 1170 ± 1600 | 2910 ± 3180 | 9380 ± 4860 | 9890 ± 5480 |
Cmax is the maximum (peak) plasma concentration over the dosing interval at steady state (ss)
| Nanogram per Milliliter (ng/mL) | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 2: GDC-0853 High Dose |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration of GDC-0853 at Steady State (Cmax,ss) | 110 ± 116 | 280 ± 223 | 591 ± 282 | 621 ± 302 |
Cmin is the minimum concentration over the dosing interval at steady state (ss)
| Nanogram per Milliliter (ng/mL) | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 2: GDC-0853 High Dose |
|---|---|---|---|---|
| Minimum Observed Plasma Concentration of GDC-0853 at Steady State (Cmin,ss) | 22.4 ± 41.0 | 54.7 ± 83.4 | 250 ± 146 | 263 ± 170 |
Collected over From randomization to end of study (approximately 22 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | 0/40 (0%) | 0/40 (0%) | 9/40 (22.5%) |
| Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | 0/109 (0%) | 1/109 (0.9%) | 18/109 (16.5%) |
| Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | 1/110 (0.9%) | 3/110 (2.7%) | 11/110 (10%) |
| Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | 0/110 (0%) | 1/110 (0.9%) | 15/110 (13.6%) |
| Cohort 1: GDC-0853 Placebo + Adalimumab | 0/111 (0%) | 2/111 (1.8%) | 16/111 (14.4%) |
| Cohort 2: GDC-0853 High Dose | 0/49 (0%) | 0/49 (0%) | 3/49 (6.1%) |
| Cohort 2: GDC-0853 Placebo | 0/49 (0%) | 0/49 (0%) | 7/49 (14.3%) |
| Event | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| PNEUMONIAInfections and infestations | 0/40 | 1/109 | 0/110 | 1/110 | 0/111 | 0/49 | 0/49 |
| MYOCARDIAL INFARCTIONCardiac disorders | 0/40 | 0/109 | 1/110 | 0/110 | 0/111 | — | — |
| CELLULITSInfections and infestations | 0/40 | 0/109 | 1/110 | 0/110 | 0/111 | 0/49 | 0/49 |
| PYELONEPHRITIS OBSTRUCTIONInfections and infestations | 0/40 | 0/109 | 1/110 | 0/110 | 0/111 | 0/49 | 0/49 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 0/40 | 0/109 | 0/110 | 1/110 | 0/111 | 0/49 | 0/49 |
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 0/40 | 0/109 | 0/110 | 1/110 | 0/111 | 0/49 | 0/49 |
| SMALL INTESTINAL DISORDERSGastrointestinal disorders | 0/40 | 0/109 | 0/110 | 0/110 | 1/111 | 0/49 | 0/49 |
| SEIZURENervous system disorders | 0/40 | 0/109 | 0/110 | 0/110 | 1/111 | 0/49 | 0/49 |
| Event | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo |
|---|---|---|---|---|---|---|---|
| URINARY TRACT INFECTIONInfections and infestations | 2/40 | 2/109 | 0/110 | 2/110 | 8/111 | 0/49 | 3/49 |
| NAUSEAGastrointestinal disorders | 2/40 | 5/109 | 3/110 | 5/110 | 1/111 | 3/49 | 1/49 |
| ANXIETYPsychiatric disorders | 0/40 | 0/109 | 0/110 | 0/110 | 0/111 | 0/49 | 3/49 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/40 | 3/109 | 3/110 | 2/110 | 6/111 | 0/49 | 0/49 |
| VOMITINGGastrointestinal disorders | 2/40 | 1/109 | 0/110 | 0/110 | 1/111 | 0/49 | 0/49 |
| ALANINE AMINOTRANFERASE INCREASEDInvestigations | 2/40 | 5/109 | 4/110 | 1/110 | 1/111 | 0/49 | 0/49 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 2/40 | 4/109 | 3/110 | 1/110 | 1/111 | 0/49 | 0/49 |
| HEADACHENervous system disorders | 2/40 | 4/109 | 5/110 | 5/110 | 0/111 | 0/49 | 0/49 |
Safety population (SAF) included all subjects that received treatment.
| Age, Categorical(Participants) | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 35 | 95 | 99 | 98 | 98 | 41 | 40 | 506 |
| >=65 years | 5 | 14 | 11 | 12 | 13 | 8 | 9 | 72 |
| Age, Continuous(Years) | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 52.3 ± 12.0 | 50.4 ± 11.0 | 49.9 ± 12.4 | 50.2 ± 11.6 | 49.9 ± 12.4 | 51.3 ± 13.2 | 54.6 ± 11.5 | 50.7 ± 12.0 |
| Sex: Female, Male(Participants) | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 35 | 92 | 85 | 90 | 87 | 37 | 37 | 463 |
| Male | 5 | 17 | 25 | 20 | 24 | 12 | 12 | 115 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska native | 0 | 8 | 12 | 11 | 9 | 6 | 5 | 51 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black of African American | 0 | 1 | 2 | 3 | 1 | 1 | 2 | 10 |
| White | 36 | 96 | 96 | 95 | 99 | 42 | 42 | 506 |
| Multiple | 3 | 2 | 0 | 1 | 1 | 0 | 0 | 7 |
| Unknown | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo | Cohort 1: GDC-0853 High Dose + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab Placebo | Cohort 1: GDC-0853 Placebo + Adalimumab | Cohort 2: GDC-0853 High Dose | Cohort 2: GDC-0853 Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 38 | 40 | 38 | 39 | 17 | 15 | 195 |
| Not Hispanic or Latino | 31 | 68 | 69 | 72 | 70 | 32 | 33 | 375 |
| Not Stated | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 3 |
| Unknown | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 5 |
Showing the first 100 of 150 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Jul 2018, 21 months.
Results were first posted in Sep 2019, 1 year 2 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenebrutinib